ProCE Banner Activity

CME

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Text Module

Review expert faculty discussion of BTK inhibitor resistance in CLL, including optimal testing and treatment sequencing to overcome resistance to prior therapy. 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 01, 2024

Expiration: March 31, 2025

Share

Faculty

Matthew S Davids

Matthew S Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Lindsey Roeker

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Target Audience

This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence in selecting treatment for CLL that takes into consideration the eventual development of resistance in order to provide the most effective and well tolerated option at each line of treatment.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Select first-line treatment for CLL that considers the eventual development of resistance to maximize duration of response and quality of life at each line of therapy

  • Describe to colleagues the incidence of de novo resistance and acquired resistance to BTKi treatments for CLL

  • Compare the efficacy and safety of BTKi agents and BTKi-based combinations

  • Select second and later lines of treatment for CLL that overcomes resistance to prior therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Matthew S Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: consultant/advisor/speaker: AbbVie, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, SecuraBio, Takeda, TG Therapeutics; researcher: Ascentage Pharma, MEI Pharma, Novartis.

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Lindsey Roeker, MD: consultant/advisor/speaker: AbbVie, Ascentage, AstraZeneca, BeiGene, Curio, DAVA, Janssen, Loxo Oncology, Pharmacyclics, Pfizer; data and safety monitoring committee: Ascentage; owner (minority ownership interest): Abbott; researcher (paid to institution): AbbVie, Adaptive Biotechnologies, Aptose Biosciences, AstraZeneca, Dren Bio, Genentech, Loxo Oncology, Pfizer, Qilu Puget Sound Biotherapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 01, 2024, through March 31, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.